Please wait while the formulary information is being retrieved.
LYRICA (PREGABALIN)
- Diabetic peripheral neuropathy
- Partial epilepsy treatment adjunct
- Fibromyalgia
- Neuropathic pain associated with spinal cord injury
- Postherpetic neuralgia
20 mg/mL oral solution
- 7.5 milliliters (150 mg) by oral route 2 times per day at the same times each day
100 mg capsule
- 1 capsule (100 mg) by oral route 3 times per day
150 mg capsule
- 1 capsule (150 mg) by oral route 2 times per day
200 mg capsule
- 1 capsule (200 mg) by oral route 3 times per day
225 mg capsule
- 1 capsule (225 mg) by oral route 2 times per day
25 mg capsule
- 1 capsule (25 mg) by oral route 3 times per day
300 mg capsule
- 1 capsule (300 mg) by oral route 2 times per day
50 mg capsule
- 1 capsule (50 mg) by oral route 3 times per day
75 mg capsule
- 1 capsule (75 mg) by oral route 2 times per day
20 mg/mL oral solution
- 7.5 milliliters (150 mg) by oral route 2 times per day at the same times each day
100 mg capsule
- 1 capsule (100 mg) by oral route 3 times per day
150 mg capsule
- 1 capsule (150 mg) by oral route 2 times per day
200 mg capsule
- 1 capsule (200 mg) by oral route 3 times per day
225 mg capsule
- 1 capsule (225 mg) by oral route 2 times per day
25 mg capsule
- 1 capsule (25 mg) by oral route 3 times per day
300 mg capsule
- 1 capsule (300 mg) by oral route 2 times per day
50 mg capsule
- 1 capsule (50 mg) by oral route 3 times per day
75 mg capsule
- 1 capsule (75 mg) by oral route 2 times per day
Diabetic peripheral neuropathy
- 2.5 milliliters (50 mg) by oral route 3 times per day at the same times each day
- 1 capsule (100 mg) by oral route 3 times per day
- 2 capsules (100 mg) by oral route 3 times per day
- 5 milliliters (100 mg) by oral route 3 times per day at the sametimes each day
Fibromyalgia
- 1 capsule (25 mg) by oral route 3 times per day
- 2 capsules (50 mg) by oral route 3 times per day
- 7.5 milliliters (150 mg) by oral route 2 times per day at the same times each day
- 1 capsule (150 mg) by oral route 2 times per day
- 2 capsules (150 mg) by oral route 2 times per day
- 2 capsules (200 mg) by oral route 2 times per day
- 1 capsule (200 mg) by oral route 2 times per day
- 11.25 milliliters (225 mg) by oral route 2 times per day at the same times each day
- 1 capsule (225 mg) by oral route 2 times per day
Neuropathic pain associated with spinal cord injury
- 3.75 milliliters (75 mg) by oral route 2 times per day at the same times each day
- 1 capsule (75 mg) by oral route 2 times per day
- 1 capsule (100 mg) by oral route 2 times per day
- 7.5 milliliters (150 mg) by oral route 2 times per day at the same times each day
- 1 capsule (150 mg) by oral route 2 times per day
- 2 capsules (150 mg) by oral route 2 times per day
- 2 capsules (200 mg) by oral route 2 times per day
- 1 capsule (200 mg) by oral route 2 times per day
- 1 capsule (225 mg) by oral route 2 times per day
- 2 capsules (300 mg) by oral route 2 times per day
- 1 capsule (300 mg) by oral route 2 times per day
- 15 milliliters (300 mg) by oral route 2 times per day at the same times each day
Partial epilepsy treatment adjunct
- 2 capsules (50 mg) by oral route 3 times per day
- 1 capsule (50 mg) by oral route 3 times per day
- 2.5 milliliters (50 mg) by oral route 3 times per day at the same times each day
- 3.75 milliliters (75 mg) by oral route 2 times per day at the same times each day
- 1 capsule (75 mg) by oral route 2 times per day
- 1 capsule (75 mg) by oral route 3 times per day
- 1 capsule (100 mg) by oral route 2 times per day
- 1 capsule (100 mg) by oral route 3 times per day
- 1 capsule (150 mg) by oral route 3 times per day
- 2 capsules (150 mg) by oral route 3 times per day
- 1 capsule (150 mg) by oral route 2 times per day
- 2 capsules (150 mg) by oral route 2 times per day
- 2 capsules (200 mg) by oral route 2 times per day
- 2 capsules (200 mg) by oral route 3 times per day
- 1 capsule (200 mg) by oral route 2 times per day
- 1 capsule (200 mg) by oral route 3 times per day
- 10 milliliters (200 mg) by oral route 3 times per day at the same times each day
- 1 capsule (225 mg) by oral route 2 times per day
- 2 capsules (300 mg) by oral route 2 times per day
- 1 capsule (300 mg) by oral route 2 times per day
- 15 milliliters (300 mg) by oral route 2 times per day at the same times each day
Postherpetic neuralgia
- 1 capsule (25 mg) by oral route 3 times per day
- 2 capsules (50 mg) by oral route 3 times per day
- 1 capsule (50 mg) by oral route 3 times per day
- 2.5 milliliters (50 mg) by oral route 3 times per day at the same times each day
- 3.75 milliliters (75 mg) by oral route 2 times per day at the same times each day
- 1 capsule (75 mg) by oral route 2 times per day
- 1 capsule (100 mg) by oral route 3 times per day
- 2 capsules (100 mg) by oral route 3 times per day
- 5 milliliters (100 mg) by oral route 3 times per day at the sametimes each day
- 7.5 milliliters (150 mg) by oral route 2 times per day at the same times each day
- 1 capsule (150 mg) by oral route 2 times per day
- 2 capsules (150 mg) by oral route 2 times per day
- 2 capsules (200 mg) by oral route 3 times per day
- 1 capsule (200 mg) by oral route 3 times per day
- 10 milliliters (200 mg) by oral route 3 times per day at the same times each day
- 1 capsule (225 mg) by oral route 2 times per day
- 2 capsules (300 mg) by oral route 2 times per day
- 1 capsule (300 mg) by oral route 2 times per day
- 15 milliliters (300 mg) by oral route 2 times per day at the same times each day
- None
Contraindicated
- sodium oxybate
- Xyrem
Severe
Moderate
- Actoplus Met
- Actoplus Met Xr
- Actos
- alogliptin-pioglitazone
- Astramorph-pf
- Avinza
- Depodur (pf)
- Duetact
- Duramorph (pf)
- Kadian
- morphine
- morphine (PF)
- morphine concentrate
- morphine liposomal (PF)
- Ms Contin
- Oseni
- pioglitazone
- pioglitazone-glimepiride
- pioglitazone-metformin
- Rhabdomyolysis
Contraindicated
- Acute decompensated heart failure
- Angioedema
- Chronic kidney disease stage 3A (moderate) GFR 45-59
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Myopathy with CK elevation
- Suicidal ideation
Severe
Moderate
- Atrioventricular block
- Chronic heart failure
- Depression
- Kidney disease with likely reduction in GFR
- Peripheral edema
- Reduced visual acuity
- Severe thrombocytopenia
- Weight gain
LYRICA (PREGABALIN)
- Diabetic peripheral neuropathy
- Partial epilepsy treatment adjunct
- Fibromyalgia
- Neuropathic pain associated with spinal cord injury
- Postherpetic neuralgia
- Ataxia
- Blurred vision
- Concentration difficulty
- Disturbance in thinking
- Dizziness
- Drowsy
- Peripheral edema
- Weight gain
- Xerostomia
More Frequent
Severe
Less Severe
- Facial edema
- Infection
- Thrombocytopenic disorder
- Accidental injury
- Acute abdominal pain
- Acute confusion
- Arthralgias
- Back pain
- Constipation
- Euphoria
- Gastroenteritis
- General weakness
- Headache disorder
- Hypesthesia
- Increased appetite
- Memory impairment
- Muscle spasm
- Orgasm disorder
- Pruritus of skin
- Sialorrhea
- Sinusitis
- Twitching
- Vertigo
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Angioedema
- Behavioral disorders
- Blistering skin
- Diplopia
- Dysarthria
- Dyskinesia
- Hypoglycemic disorder
- Kidney stone
- Prolonged PR interval
- Suicidal ideation
- Tinnitus
- Urticaria
- Wheezing
Less Severe
- Abdominal distension
- Acute bacterial otitis media
- Amenorrhea
- Bronchitis
- Chest pain
- Conjunctivitis
- Cramps in legs
- Depersonalization
- Diarrhea
- Dysmenorrhea
- Dyspareunia
- Dyspnea
- Dysuria
- Ecchymosis
- Edema
- Erectile dysfunction
- Erythema
- Fatigue
- Fever
- Flatulence
- Flu-like symptoms
- Gait abnormality
- Gynecomastia
- Hematuria
- Hypertonia
- Increased urinary frequency
- Libido changes
- Muscle weakness
- Myalgias
- Nail disorders
- Nausea
- Nervousness
- Nystagmus
- Skin rash
- Stupor
- Symptoms of anxiety
- Tremor
- Urinary incontinence
- Visual changes
- Vomiting
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Pregabalin
Safety and efficacy not established for age < 1 month.
- 1 Day – 29 Days
- Safety and efficacy not established for age < 1 month.
Pregabalin
- Severity Level:
2
- Additional Notes: Insuff human data; animal data sug dev tox at >10 times mrhd
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Pregabalin
Limited data suggest excretion in very low amounts
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | Limited data suggest excretion in very low amounts |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Pregabalin
Renal-Adjust dose for CrCl < 60 mL/min. Neuro/Psych-Can cause ataxia, impaired psychomotor function, syncope, and additional falls. Avoid concomitant opioids except when transitioning therapy. Pulmonary-Elderly may be at higher risk for respiratory depression. Risk is highest in elderly with pre-existing chronic pulmonary disease or with concomitant use of opioids.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | N | Y | Y | N |
BEERS: Y HEDIS: Y STOPP: Y
No Known Risk
None
- None
| Diabetic peripheral neuropathy | |
| E08.40 | Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified |
| E08.42 | Diabetes mellitus due to underlying condition with diabetic polyneuropathy |
| E09.40 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified |
| E09.42 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy |
| E10.40 | Type 1 diabetes mellitus with diabetic neuropathy, unspecified |
| E10.42 | Type 1 diabetes mellitus with diabetic polyneuropathy |
| E11.40 | Type 2 diabetes mellitus with diabetic neuropathy, unspecified |
| E11.42 | Type 2 diabetes mellitus with diabetic polyneuropathy |
| E13.40 | Other specified diabetes mellitus with diabetic neuropathy, unspecified |
| E13.42 | Other specified diabetes mellitus with diabetic polyneuropathy |
| Fibromyalgia | |
| M79.7 | Fibromyalgia |
| Neuropathic pain associated with spinal cord injury | |
| G59 | Mononeuropathy in diseases classified elsewhere |
| G63 | Polyneuropathy in diseases classified elsewhere |
| Partial epilepsy treatment adjunct | |
| G40.0 | Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset |
| G40.00 | Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, not intractable |
| G40.009 | Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, not intractable, without status epilepticus |
| G40.01 | Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable |
| G40.019 | Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, without status epilepticus |
| G40.1 | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures |
| G40.10 | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable |
| G40.109 | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, without status epilepticus |
| G40.11 | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable |
| G40.119 | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, without status epilepticus |
| G40.2 | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures |
| G40.20 | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable |
| G40.209 | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, without status epilepticus |
| G40.21 | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable |
| G40.219 | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, without status epilepticus |
| Postherpetic neuralgia | |
| B02.22 | Postherpetic trigeminal neuralgia |
| B02.23 | Postherpetic polyneuropathy |
| 0-9 | A-Z |
|---|---|
| B02.22 | Postherpetic trigeminal neuralgia |
| B02.23 | Postherpetic polyneuropathy |
| E08.40 | Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified |
| E08.42 | Diabetes mellitus due to underlying condition with diabetic polyneuropathy |
| E09.40 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified |
| E09.42 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy |
| E10.40 | Type 1 diabetes mellitus with diabetic neuropathy, unspecified |
| E10.42 | Type 1 diabetes mellitus with diabetic polyneuropathy |
| E11.40 | Type 2 diabetes mellitus with diabetic neuropathy, unspecified |
| E11.42 | Type 2 diabetes mellitus with diabetic polyneuropathy |
| E13.40 | Other specified diabetes mellitus with diabetic neuropathy, unspecified |
| E13.42 | Other specified diabetes mellitus with diabetic polyneuropathy |
| G40.0 | Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset |
| G40.00 | Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, not intractable |
| G40.009 | Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, not intractable, without status epilepticus |
| G40.01 | Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable |
| G40.019 | Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, without status epilepticus |
| G40.1 | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures |
| G40.10 | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable |
| G40.109 | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, without status epilepticus |
| G40.11 | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable |
| G40.119 | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, without status epilepticus |
| G40.2 | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures |
| G40.20 | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable |
| G40.209 | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, without status epilepticus |
| G40.21 | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable |
| G40.219 | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, without status epilepticus |
| G59 | Mononeuropathy in diseases classified elsewhere |
| G63 | Polyneuropathy in diseases classified elsewhere |
| M79.7 | Fibromyalgia |
Formulary Reference Tool